Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 38% Improvement Relative Risk Santoro et al. Aspirin for COVID-19 LATE TREATMENT Is late treatment with aspirin beneficial for COVID-19? PSM retrospective 7,824 patients in multiple countries (Jan - May 2020) Lower mortality with aspirin (p=0.017) Santoro et al., J. the American Heart Association, doi:10.1161/JAHA.121.024530 Favors aspirin Favors control
Aspirin Therapy on Prophylactic Anticoagulation for Patients Hospitalized With COVID-19: A Propensity Score-Matched Cohort Analysis of the HOPE-COVID-19 Registry
Santoro et al., Journal of the American Heart Association, doi:10.1161/JAHA.121.024530
Santoro et al., Aspirin Therapy on Prophylactic Anticoagulation for Patients Hospitalized With COVID-19: A Propensity.., Journal of the American Heart Association, doi:10.1161/JAHA.121.024530
Jun 2022   Source   PDF  
  All Studies   Meta
HOPE-COVID-19 PSM retrospective 7,824 patients, comparing prophylactic anticoagulation with and without additional treatment with aspirin in hospitalized patients, showing lower mortality with aspirin treatment.
risk of death, 38.0% lower, HR 0.62, p = 0.02, treatment 360, control 2,949.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Santoro et al., 22 Jun 2022, retrospective, propensity score matching, multivariable, multiple countries, peer-reviewed, 31 authors, study period 16 January, 2020 - 30 May, 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Abstract: Journal of the American Heart Association ORIGINAL RESEARCH Aspirin Therapy on Prophylactic Anticoagulation for Patients Hospitalized With COVID-­19: A Propensity Score-­ Matched Cohort Analysis of the HOPE-­ COVID-­19 Registry Francesco Santoro , MD, PhD*; Ivan J. Núñez-­Gil, MD, PhD*; Enrica Vitale, MD; María C. Viana-­Llamas , MD; Rodolfo Romero , MD; Charbel Maroun Eid , MD; Gisela Feltes Guzman, MD; Victor Manuel Becerra-­Muñoz , MD; Inmaculada Fernández Rozas, MD; Aitor Uribarri , MD; Emilio Alfonso-­Rodriguez , MD; Marcos García Aguado, MD; Jia Huang, MD; Alex Fernando Castro Mejía , MD; Juan Fortunato Garcia Prieto, MD; Javier Elola , MD; Fabrizio Ugo, MD; Enrico Cerrato , MD; Jaime Signes-­Costa, MD; Sergio Raposeiras Roubin , MD; Jorge Luis Jativa Mendez , MD; Carolina Espejo Paeres, MD; Alvaro López Masjuan, MD; Francisco Marin, MD; Federico Guerra , MD; Ibrahim El-­Battrawy , MD; Bernardo Cortese , MD; Harish Ramakrishna , MD; Julian Perez-­Villacastín , MD; Antonio Fernandez-­Ortiz , MD; Natale Daniele Brunetti , MD, PhD BACKGROUND: COVID-­19 is an infectious illness, featured by an increased risk of thromboembolism. However, no standard antithrombotic therapy is currently recommended for patients hospitalized with COVID-­19. The aim of this study was to evaluate safety and efficacy of additional therapy with aspirin over prophylactic anticoagulation (PAC) in patients hospitalized with COVID-­19 and its impact on survival. METHODS AND RESULTS: A total of 8168 patients hospitalized for COVID-­19 were enrolled in a multicenter-­international prospective registry (HOPE COVID-­19). Clinical data and in-­hospital complications, including mortality, were recorded. Study population included patients treated with PAC or with PAC and aspirin. A comparison of clinical outcomes between patients treated with PAC versus PAC and aspirin was performed using an adjusted analysis with propensity score matching. Of 7824 patients with complete data, 360 (4.6%) received PAC and aspirin and 2949 (37.6%) PAC. Propensity-­score matching yielded 298 patients from each group. In the propensity score-­matched population, cumulative incidence of in-­hospital mortality was lower in patients treated with PAC and aspirin versus PAC (15% versus 21%, Log Rank P=0.01). At multivariable analysis in propensity matched population of patients with COVID-­19, including age, sex, hypertension, diabetes, kidney failure, and invasive ventilation, aspirin treatment was associated with lower risk of in-­hospital mortality (hazard ratio [HR], 0.62; [95% CI 0.42–­0.92], P=0.018). CONCLUSIONS: Combination PAC and aspirin was associated with lower mortality risk among patients hospitalized with COVID-­19 in a propensity score matched population compared to PAC alone. Key Words: anticoagulation ■ antiplatelet therapy ■ aspirin ■ COVID-­19 ■ prognosis ■ risk prediction Correspondence to: Natale Daniele Brunetti, MD, PhD, FESC, Department of Medical & Surgical Sciences, University of Foggia, viale Pinto 1, Foggia, N/A 71122, Italy. Email: *F. Santoro and I. J. Núñez-­Gil contributed equally and are co-­first authors. Supplemental Material is available at https://www.ahajo​​10.1161/JAHA.121.024530 For Sources of Funding and Disclosures, see page 7. © 2022 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop